Bolt Biotherapeutics is a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Bolt’s proprietary Boltbody™ Immune-stimulating Antibody Conjugate (ISAC) approach uses immunostimulants to engage and activate myeloid cells that directly kill tumor cells. This leads to the conversion of immunologically “cold” tumors to “hot” tumors.
Our lead clinical-stage candidate, BDC-1001, is a Boltbody ISAC comprised of a HER2-targeting biosimilar of trastuzumab conjugated to one of our proprietary TLR7/8 agonists for the treatment of patients with HER2-positive solid tumors. Data from our completed Phase 1 dose-escalation trial support the advancement of BDC-1001 into Phase 2 studies.
Bolt is also advancing BDC-3042, a proprietary myeloid modulating agonistic antibody targeting Dectin-2. BDC-3042 is designed to reprogram tumor-associated macrophages (TAMs) into immunostimulatory cells that enhance innate and adaptive anti-tumor immunity. Preclinical data support the advancement of BDC-3042 into the clinic in 2023.
December 5, 2023
Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®Read More
November 9, 2023
Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateRead More
November 7, 2023
Bolt Biotherapeutics to Present at Stifel 2023 Healthcare ConferenceRead More